Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Hereditary Sensory and Autonomic Neuropathies 1Cholangiocarcinoma 1Bile Duct Neoplasms 1

Interventions

Specimen Handling 181Magnetic Resonance Spectroscopy 138Biopsy 100Immunoglobulin G 38Disulfides 38Cisplatin 37Nivolumab 36Platinum 35Paclitaxel 351,2-diaminocyclohexaneplatinum II citrate 35Radiation 34Cyclophosphamide 34Carboplatin 33Taxes 32Radiotherapy 28pembrolizumab 26X-Rays 26Doxorubicin 24Bevacizumab 24olaparib 22atezolizumab 21Gemcitabine 19Vincristine 18Prednisone 17Etoposide 17Leucovorin 16Cytarabine 16fludarabine 15durvalumab 15Phantoms, Imaging 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × tivozanib × 30 days × Clear all
NCT04645160 2026-06-05

Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
31 enrolled
Gastrointestinal

Bile Duct Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡